STEPTOE LLP

Lobbying for OREXO US, INC. · Pharmaceuticals / health products

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · New Jersey · House · Senate · $150,000.00 income · posted Jul 20, 2026

Lobbying activity 2

Alcohol and Drug Abuse

Advocacy on xylazine and adultered-opioid overdose solutions and federal funding.

Budget/Appropriations

Advocacy on xylazine and adultered-opioid overdose solutions and federal funding.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.